FilingReader Intelligence
Haisco Pharmaceutical gets approval for autoimmune drug trial
August 7, 2025 at 05:17 PM UTC•By FilingReader AI
Haisco Pharmaceutical Group obtained clinical trial approval from the National Medical Products Administration for HSK47388 tablets, an oral drug for treating autoimmune diseases.
The Class 1 chemical drug showed effective inhibition of inflammatory reactions in preclinical rat studies with good tolerability and wide safety margins.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime